Roche reports positive data from combination leukaemia therapy trial

Roche has announced the findings of a phase III trial that demonstrates the potential benefits of a new combination treatment for chronic lymphocytic leukaemia.

Data from the pivotal MURANO study showed that a combination of Venclexta/Venclyxto plus MabThera/Rituxan delivered better results for people with relapsed or refractory chronic lymphocytic leukaemia than bendamustine plus MabThera/Rituxan.

A fixed duration of treatment with the new regimen was associated with a significant reduction in the risk of disease progression or death of 83 percent, with no new safety signals observed.

Given the scale of the benefits on offer compared to the current standard of care, it is hoped that regulatory approval for the regimen will be forthcoming.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "The MURANO study results indicate that Venclexta/Venclyxto plus MabThera/Rituxan has the potential to provide an important new chemotherapy-free option for people with previously treated chronic lymphocytic leukaemia."

Venclexta/Venclyxto has also shown efficacy in the treatment of several other blood cancers, including acute myeloid leukaemia and multiple myeloma.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.